Performance of the United States Vaccine Injury Compensation Program (VICP): 1988-2019.

Area of Science:

• Public Health
• Immunization Safety
• Health Economics

Background:

• The United States (US) prioritizes vaccination benefits, investing in vaccine development.
• Recognizing minimal risks, the US established the Vaccine Injury Compensation Program (VICP) in 1986.
• The VICP uses vaccine excise taxes to fund compensation for vaccine-related injuries.

Purpose of the Study:

• To review the operational experience, covered vaccines and injuries, claims data, and financial status of the VICP.
• To assess the safety record of vaccines within the VICP framework.
• To analyze the economic viability and performance of the VICP fund.

Main Methods:

• Analysis of VICP claims data, including types of injuries and vaccines involved.
• Review of financial records and economic performance of the VICP fund.
• Examination of the program's history and operational maturity.

Main Results:

• Vaccines demonstrate an excellent safety track record.
• Evidence suggests some injuries are specifically linked to vaccine administration.
• The VICP fund is financially sound.

Conclusions:

• The VICP effectively manages compensation for vaccine-related injuries.
• Vaccine safety is robust, with rare exceptions related to administration.
• The program's financial structure ensures its continued operation.